Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$9.82
-1.7%
$9.46
$3.75
$11.54
$157.32M2.7393,437 shs22,135 shs
INmune Bio, Inc. stock logo
INMB
INmune Bio
$2.32
-4.3%
$5.83
$1.89
$11.64
$54.82M1.34853,953 shs810,748 shs
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$3.79
+5.1%
$3.77
$3.36
$12.22
$152.84M1.114,434 shs697 shs
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
$2.13
-3.8%
$0.82
$0.13
$3.29
$266.79M2.044.94 million shs2.72 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
0.00%-7.59%+9.06%+137.29%+998,999,900.00%
INmune Bio, Inc. stock logo
INMB
INmune Bio
0.00%+4.76%-62.07%-66.76%-70.05%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
0.00%+2.23%-1.52%-3.85%-44.92%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
0.00%-11.60%+819.68%+221.97%+139.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
1.0827 of 5 stars
3.50.00.00.00.00.80.0
INmune Bio, Inc. stock logo
INMB
INmune Bio
1.5898 of 5 stars
3.31.00.00.01.11.70.6
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
2.9495 of 5 stars
3.85.00.00.00.00.00.6
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
3.9214 of 5 stars
4.35.00.00.03.11.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
3.00
Buy$20.00103.67% Upside
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.57
Moderate Buy$18.40694.82% Upside
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
3.50
Strong Buy$12.00217.04% Upside
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.60
Moderate Buy$5.63164.87% Upside

Current Analyst Ratings Breakdown

Latest VOR, MOLN, ACOG, and INMB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $8.00
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Underperform
6/30/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
6/30/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$3.00
6/26/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Outperform
5/16/2025
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/9/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/9/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Perform$6.00 ➝ $6.00
5/9/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
5/8/2025
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/A$2.59 per shareN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
$10K5,458.77N/AN/A$1.45 per share1.60
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$5.65M27.05N/AN/A$3.99 per share0.95
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$14.64M-$1.20N/AN/AN/A-65.83%-48.21%8/11/2025 (Estimated)
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$61.39M-$1.92N/AN/AN/AN/A-42.20%-38.12%8/25/2025 (Estimated)
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/A-$1.51N/AN/AN/AN/AN/AN/AN/A

Latest VOR, MOLN, ACOG, and INMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$0.84N/AN/AN/A$2.32 millionN/A
8/7/2025Q2 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.37N/AN/AN/AN/AN/A
5/15/2025Q1 2025
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 million
5/15/2025Q1 2025
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.3855-$0.50-$0.1145-$0.50N/AN/A
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
17.14
16.83
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.64
2.64
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/A
15.28
15.28
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
26.55%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
97.29%

Insider Ownership

CompanyInsider Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
14.00%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
5.93%
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A16.02 million13.78 millionN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
1023.58 million15.17 millionOptionable
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
18040.38 million37.98 millionNot Optionable
Vor Biopharma Inc. stock logo
VOR
Vor Biopharma
140124.96 million65.45 millionNot Optionable

Recent News About These Companies

Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright
Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500
Vor Biopharma Inc. Stock Grades - Barron's

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alpha Cognition stock logo

Alpha Cognition NASDAQ:ACOG

$9.82 -0.17 (-1.70%)
As of 11:33 AM Eastern

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$2.32 -0.11 (-4.34%)
As of 11:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$3.78 +0.19 (+5.14%)
As of 11:41 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Vor Biopharma stock logo

Vor Biopharma NYSE:VOR

$2.12 -0.09 (-3.85%)
As of 11:47 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.